Bacteriophages, Part B: 83 (Advances in Virus Research)
Book file PDF easily for everyone and every device.
You can download and read online Bacteriophages, Part B: 83 (Advances in Virus Research) file PDF Book only if you are registered here.
And also you can download or read online all Book PDF file that related with Bacteriophages, Part B: 83 (Advances in Virus Research) book.
Happy reading Bacteriophages, Part B: 83 (Advances in Virus Research) Bookeveryone.
Download file Free Book PDF Bacteriophages, Part B: 83 (Advances in Virus Research) at Complete PDF Library.
This Book have some digital formats such us :paperbook, ebook, kindle, epub, fb2 and another formats.
Here is The CompletePDF Book Library.
It's free to register here to get Book file PDF Bacteriophages, Part B: 83 (Advances in Virus Research) Pocket Guide.
Write a Review. Related Searches. Advances in Photovoltaics: Part 2. Semiconductors and Semimetals has distinguished itself through the careful selection of well-known authors, editors, and Semiconductors and Semimetals has distinguished itself through the careful selection of well-known authors, editors, and contributors. Originally widely known as the Willardson and Beer Series, it has succeeded in publishing numerous landmark volumes and chapters.
The series publishes timely, highly View Product. Advances in Photovoltaics: Part 3.
- Evergreen Phage Lab.
- Pagans in the Promised Land: Decoding the Doctrine of Christian Discovery?
- Complete Guide to Writing Effective Resume Cover Letters: Step-by-Step Instructions?
This volume is the third of a set of seven on the topic of photovoltaics. Solar cell-related technologies covered here include: ribbon silicon; heterojunction crystalline silicon; wafer equivalent crystalline silicon; and other advanced silicon solar cell structures and processes.
Advances in Quantum Chemistry. Advances in Quantum Chemistry, Volume 77, presents surveys of current topics in this rapidly developing Advances in Quantum Chemistry, Volume 77, presents surveys of current topics in this rapidly developing field, one that has emerged at the cross section of the historically established areas of mathematics, physics, chemistry and biology. It features detailed reviews written Advances in Botanical Research publishes in-depth and up-to-date reviews on a wide range of topics Advances in Botanical Research publishes in-depth and up-to-date reviews on a wide range of topics in plant sciences.
The series features a wide range of reviews by recognized experts on all aspects of plant genetics, biochemistry, cell biology, molecular biology, Edited by Jean-Claude Kader and Michel Delseny and supported by an international Editorial Board, Advances in Botanical Research publishes in-depth and up-to-date reviews on a wide range of topics in plant sciences.
The series features a wide range of reviews by This special issue of The Enzymes is targeted towards researchers in biochemistry, molecular and cell This special issue of The Enzymes is targeted towards researchers in biochemistry, molecular and cell biology, pharmacology, and cancer.
Labrie, S. Moineau, Liapikou, A. Torres, Lin, T. Chen, Lu, T. Malik, D. Matsuda, T. Daly, McCarville, J.
Verdu, McVay, C. A Fralick, Fralick, Nemeth, J.
Kuster, Snopkova, S. Pei, R. Lamas-Samanamud, Pires, D. Pourmand, A. Shesser, Qadir, M. I, Rangel, R. Arap, Rhoads, D. Sulakvelidze, Roach, D. Donovan, Rose, T. Pirnay, Ross, A. Sarker, S. Semler, D. Dennisa, Singla, S. Chhibber, Smith, H. Huggins, Stanford, K.
Bacteriophages: Their Structural Organisation and Function
Johnson, Staquicini, F. Sulakvelidze, A. Morris, Tanji, Y. Some of these molecules have been developed as therapeutics and are currently in clinical or preclinical trials; on the other hand, others have been crucial to describe protein-protein interactions and revealed important therapeutic targets [ 19 , 20 ]. Briefly, this method focuses on the construction of a library of peptides or antibody variants, which are then selected for their affinity to the target of interest since they are fused to a phage-coat protein.
On the other hand, pIII can be used for larger peptides, resulting only in a slight loss of infectivity in a few cases [ 21 ]. Each library is composed by phagemid vectors containing only the sequence of a phage-coat protein fused to the peptide of interest; therefore, a helper phage with a reduced packaging efficiency is needed in order to obtain a population of phages both infectious and composed by modified coating proteins.
The biopanning procedure is then performed and phages are selected for their ability to bind the antigen of interest.
Bacteriophages and Their Immunological Applications against Infectious Threats
Many factors must be taken into account: library variability, target conformation, affinity, and avidity of the molecules exposed on phages. As mentioned, phage display has been widely used to find novel therapeutics against pathogens, particularly mAbs. This has been possible through two different biopanning strategies: using specific molecular targets, such as enzymes or membrane receptors, or using whole viruses or bacterial cells.
The main difference between these two approaches is that the second one allows the identification of pathogen structures not already identified as drug targets. Moreover, surface antigens often present motifs able to elicit non-neutralizing mAbs and elude host immune response, so the screening procedure of the biopanning outcome must be done properly in order to identify only the few effective molecules.
Several human infectious diseases have been successfully addressed for drug discovery using phage display. As stated above, many of the molecules developed using phage display technique are currently in clinical trials or under evaluation at a preclinical stage. MedImmune developed motavizumab, a version of their lead compound against RSV infection palivizumab which was optimized by enhancing its affinity to the target [ 35 ].
- Could You Succeed as a Manager?!
- Home of the biennial Evergreen International Phage Biology Meeting;
- Canadian Journal of Microbiology;
- The View From Here.
- Related Articles!
Its target is phosphatidylserine, a molecule that is located in the inner part of the cell membrane of healthy cells, but becomes exposed on the surface of infected cells or solid cancer cells, allowing their immune evasion. Moreover, Human Genome Sciences developed raxibacumab for anthrax using a part of the toxin itself, the B.
Neutralizing mAbs are very useful as therapeutics but can also be of great importance for the identification of protective epitopes on pathogen structures. In fact, the characterization of these regions on viruses and bacteria could suggest which elements should be included into a vaccine formulation in order to be effective.
To date, there are several human infectious diseases that cannot be treated with vaccination, since all the approaches tested so far proved to be unsuccessful. One of the causes of failure is the nature of the antigens included into the vaccine. In fact, the use of recombinant proteins may limit, though not eliminate, the mechanisms of immunodominance that pathogens use to evade host immune response.
Immunodominant epitopes are those regions that can be mutated without affecting the pathogen protein functions, both rerouting the adaptive immune response against non-neutralizing epitopes and masking epitopes that can impair infection mechanisms. Thus, bacterial and viral proteins often elicit a varying humoral response, with a minimal neutralizing fraction, unable to defeat the infection [ 39 — 41 ]. Moreover, also antibody-mediated interference has been widely described [ 22 , 42 ]. Dulbecco et al. Later observations in both chronic and acute infections confirmed this assumption.
Two mechanisms have been proposed for this evasion strategy: non-nAbs interference by steric hindrance due to proximity of neutralizing and non-neutralizing epitopes; inhibition of binding of nAbs due to epitope conformational changes caused by non-nAbs binding to the pathogen protein. Furthermore, it has been speculated that non-nAbs may enhance infections through interaction with Fc receptors or complement receptors [ 44 ].
On the other hand, neutralizing mAbs as molecular probes could be extremely useful for a rational design of vaccine formulations: the administration of their mimotopes should elicit only an effective humoral response against pathogens [ 45 , 46 ].
Canadian Journal of Microbiology
For this purpose, phage display technique has been widely employed: HCV, HIV, and Plasmodium falciparum proteins are just examples of molecular targets used in the biopanning procedure for epitope mapping [ 26 , 47 , 48 ]. In addition, phage particles themselves can induce both cellular and humoral immune response when recognised by the immune system [ 49 ]. Moreover, they proved to be unaffected by harsh physical and chemical conditions, resulting suitable for vaccine delivery [ 50 ].
In fact, these peculiar characteristics, as well as cost-effective production and ease of modification, made bacteriophages attractive for industrial development of phage-based vaccines. Two different approaches have been developed: the first one is based on phage particles with antigens transcriptionally fused to their coat proteins, resembling the phage display technique described above. This strategy proved to be effective against Yersinia pestis [ 51 ], where T4 phages displayed an engineered structural subunit of the pathogen on its capsid, and against HIV and influenza, using phage T4 and T7, respectively [ 52 , 53 ].
Home of the biennial Evergreen International Phage Biology Meeting
The second approach consists of phage DNA vaccines: the antigen gene is delivered by phages into antigen-presenting cells to be expressed and processed by them, leading to enhanced immune response compared to naked DNA delivery. Due to their high level of organization, their unique morphology, and biological properties, bacteriophages appear as sophisticated nanomachines and, as described above, have been immediately employed for therapeutic purposes. Typically, only lytic phages are exploited for phage therapy: firstly, because they kill the host bacteria in a more efficient manner; subsequently because, after lysogenic induction, temperate phages can transfer bacteria DNA fragments to other species, and if these fragments contain gene-encoding toxins or antibiotic resistance elements, they could generate new dangerous bacteria.
- Frontiers | Perspectives of Phage Therapy in Non-bacterial Infections | Microbiology!
- Bacteriophage-based tools: recent advances and novel applications?
- Advances in Virus Research. Bacteriophages, part A. Preface..
- Bacteriophages, Part B: Volume 83?
On the contrary, lytic phages are unable to perform transduction, thus ensuring a safer profile. Nowadays, many bacteria have collected multiple resistance mechanisms, thus rendering some antibiotic classes useless. Beyond the quite high level of natural resistance, patients are concomitantly treated with broad-spectrum antibiotic molecules, increasing the rate of blind selection of multidrug resistance isolates MDR. In hospital settings, Enterococcus faecium , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumannii , Pseudomonas aeruginosa , and Enterobacter cloacae ESKAPE are examples of multidrug-resistant strains that solicit novel therapeutic measures [ 56 ].
This challenge forced modern medicine to review methods against bacterial infections, reconsidering the beneficial potential of phages. In , the Food and Drug Administration FDA approved the first Phase I clinical trial evaluating the safety of an eight-phage cocktail able to kill Staphylococcus aureus , Pseudomonas aeruginosa , and Escherichia coli ; 42 patients with venous leg ulcers were treated and a high-safety profile was demonstrated ClinicalTrials.
This study aimed at demonstrating the potential of a novel therapy for childhood diarrhea, a major cause of morbidity and deaths in Bangladesh and other developing countries, and thus a priority for improving child health: as shown in Table 1 , oral phages showed a safe gut transit, even if it failed to achieve intestinal amplification and did not improve diarrhea outcome. This was possibly related to insufficient phage coverage and too low E.
The treatment uses GMP-produced cocktails of anti- E.